Regentis Biomaterials Ltd. (NYSE American: RGNT) announced that the U.S. Patent and Trademark Office has issued a new patent titled “Organic Solvent Free Compositions Comprising Protein-Polymer Conjugates and Uses Thereof,” covering a liquid, ready-to-use formulation of its lead product, GelrinC, as well as improved production processes that eliminate the use of organic solvents. The patent focuses on GelrinC’s liquid formulation, which is designed to simplify surgical procedures and improve patient experience by conforming precisely to cartilage wounds before being cured with UV light to form a temporary elastomeric implant.
According to the company, the patent provides protection for GelrinC through 2038 and comes as Regentis has surpassed 50% enrollment in its pivotal U.S. Food and Drug Administration clinical trial for knee cartilage repair. Executive Chairman Dr. Ehud Geller highlighted the significance of the patent in strengthening the company’s intellectual property portfolio and advancing its mission to address the unmet need in cartilage repair.
Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions. Its Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC, a cell-free, off-the-shelf hydrogel, is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The company estimates that approximately 470,000 cases for cartilage knee repair occur annually in the U.S., where no off-the-shelf treatment is currently available.
The new patent covers a liquid formulation that eliminates the need for organic solvents in production, potentially streamlining manufacturing and enhancing safety. This formulation is intended to be injected into the cartilage wound and then cured with UV light, creating an implant that supports tissue regeneration. The patent’s expiration in 2038 provides long-term exclusivity for Regentis as it progresses through clinical trials and toward potential commercialization.
For more information, visit https://www.regentis.co.il/.
To view the full press release, visit https://ibn.fm/bB9os.
